【ChiCTR-ONC-14004780】對原發性開角型青光眼、原發性閉角型青光眼或高眼壓病人施用0.0015% Tafluprost(他氟前列素)滴眼液後的24小時眼球內壓概況的研究
ChiCTR-ONC-14004780
正在进行
/
/
/
2014-06-10
/
/
Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma, Ocular Hypertension
對原發性開角型青光眼、原發性閉角型青光眼或高眼壓病人施用0.0015% Tafluprost(他氟前列素)滴眼液後的24小時眼球內壓概況的研究
對原發性開角型青光眼、原發性閉角型青光眼或高眼壓病人施用0.0015% Tafluprost(他氟前列素)滴眼液後的24小時眼球內壓概況的研究
對原發性開角型青光眼、原發性閉角型青光眼或高眼壓病人施用0.0015% Tafluprost(他氟前列素)滴眼液後的24小時眼球內壓概況的研究
单臂
Ⅳ期
NA
/
Santen Pharmaceutical Co., Ltd.
/
15
/
2014-06-24
1990-01-01
/
1) Primary open angle glaucoma, primary angle closure glaucoma or ocular hypertension; 2) Above those who are currently on anti-glaucoma medication (beta-blocker, carbonic anhydrase inhibitor or their combination) and insufficiently controlled; 3) Baseline IOP is 21mmHg or higher (for PACG patient, IOP is to be 21mmHg or higher after laser iridotomy or laser iridoplasty is conducted); 4) Those who can visit the clinic on the designated day as instructed by the physician.;
请登录查看1) History of intra-ocular surgery (not including laser iridotomy or laser iridoplasty conducted for PACG patients); 2) In case of primary angle closure, laser iridotomy or laser iridoplasty within one month prior to giving the informed consent is conducted; 3) Patients who are treated by prostaglandin analogues or its combinations; 4) History of drug allergy (hypersensitivity) to the drugs to be used during the study period (anesthetic ophthalmic solution, fluorescein, etc.) or similar drugs to the investigational product; 5) Presence of any corneal disorder that may interfere with accurate IOP measurement using applanation tonometry; 6) Presence of corneal disorder that may interfere with accurate 24 hour IOP measurement using contact lens device; 7) Patients who are treated by steroids.(e.g. dexamethasone, hydrocortisone sodium succinate, prednisolone acetate); 8) Female patients who are pregnant, nursing or planning a pregnancy; 9) Patients wearing glasses with metal frames; 10) Patients with severe dry eye syndrome.;
请登录查看Santen Pharmaceutical Co., Ltd.
/
Santen Pharmaceutical Co., Ltd.的其他临床试验
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong的其他临床试验
- The effect of Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors on Diabetic Retinal Disease
- 利用下一代蛋白質組學技術鑑定淚膜中青光眼的生物標誌物
- 比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞 的手術療效
- 低濃度阿托品眼藥水在近視發病預防之研究
- 比效玻璃體注射類固醇(triamcinolone acetonide)及抗血管內皮生長因子藥物(ranibizumab)聯合療法和單一注射抗血管內皮生長因子藥物(ranibizumab)治療新生血管老年性黃斑病變之療效及安全性的前膽性研究
- 對原發性開角型青光眼、原發性閉角型青光眼或高眼壓病人施用0.0015% Tafluprost(他氟前列素)滴眼液後的24小時眼球內壓概況的研究
最新临床资讯
-
诺华:CFB抑制剂终止狼疮肾炎二期临床
医药笔记2026-10-17
-
泽安生物医药:实体瘤MCE启动一期临床
医药笔记2026-10-17
-
药明康德2026-10-17
-
沃森生物2026-10-16
-
罕见病信息网2026-10-16
-
武警特色医学中心2026-10-16
-
生物经纬2026-10-16
-
良医汇肿瘤资讯2026-10-16
-
BioMed科技2026-10-16
-
蒲公英资讯2026-10-16
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-10-26
-
2026-10-25
-
2026-10-25
-
摩熵咨询 33 51
-
摩熵咨询 20 3
-
摩熵咨询 20 10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
-
颁布机构:国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构:国家药品监督管理局 2026-09-10
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-10-23
-
2026-10-23
-
2026-10-21
-
摩熵咨询 35 83
-
摩熵咨询 28 71
-
摩熵咨询 34 47
-
颁布机构:国家药品监督管理局 2026-10-19
-
颁布机构:国家市场监督管理总局 2026-10-16
-
颁布机构:国家市场监督管理总局 2026-09-30
